E-submission
Search
- Page Path
- HOME > Search
Original Article
- Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
- So Young Kim, Kyung Un Choi, Chungsu Hwang, Hyung Jung Lee, Jung Hee Lee, Dong Hoon Shin, Jee Yeon Kim, Mee Young Sol, Jae Ho Kim, Ki Hyung Kim, Dong Soo Suh, Byung Su Kwon
- J Pathol Transl Med. 2019;53(4):244-252. Published online May 2, 2019
- DOI: https://doi.org/10.4132/jptm.2019.04.16
- 7,139 View
- 126 Download
- 6 Web of Science
- 6 Crossref
-
Abstract
PDF - Background
Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis.
Methods
Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy.
Results
CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001).
Conclusions
Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect. -
Citations
Citations to this article as recorded by
- Advances in the Study of CD109 in Tumors
平慧 周
Medical Diagnosis.2024; 14(02): 167. CrossRef - Identification of CD109 in the extracellular vesicles derived from ovarian cancer stem-like cells
Ye Eun Kim, Jun Se Kim, Min Joo Shin, Seo Yul Lee, Dae Kyoung Kim, Nam-Kyung Lee, Yang Woo Kwon, Kyung-Un Choi, Dong-Soo Suh, Byoung Soo Kim, Sanghwa Jeong, Jae Ho Kim
BMB Reports.2024; 57(12): 527. CrossRef - CD109 Promotes Drug Resistance in A2780 Ovarian Cancer Cells by Regulating the STAT3-NOTCH1 Signaling Axis
Jun Se Kim, Min Joo Shin, Seo Yul Lee, Dae Kyoung Kim, Kyung-Un Choi, Dong-Soo Suh, Dayea Kim, Jae Ho Kim
International Journal of Molecular Sciences.2023; 24(12): 10306. CrossRef - CD109 facilitates progression and 5-fluorouracil resistance of nasopharyngeal carcinoma
Zhenwei Zhu, Fang Zhou, Cheng Mao
Materials Express.2022; 12(9): 1189. CrossRef - Usefulness of CD109 expression as a prognostic biomarker in patients with cancer
Hyun Min Koh, Hyun Ju Lee, Dong Chul Kim
Medicine.2021; 100(11): e25006. CrossRef - Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma
Sumitaka Hagiwara, Eiichi Sasaki, Yasuhisa Hasegawa, Hidenori Suzuki, Daisuke Nishikawa, Shintaro Beppu, Hoshino Terada, Michi Sawabe, Masahide Takahashi, Nobuhiro Hanai
Cancer Medicine.2021; 10(4): 1335. CrossRef
- Advances in the Study of CD109 in Tumors
First
Prev
